Regulatory actions of insulin-like growth factor-binding proteins

Trends in Endocrinology and Metabolism

Volumn 9, Issue 5, 1998, Pages 176-183

  Rechler, Matthew M ^a   Clemmons, David R ^b  

^a Growth and Development Section   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

APOPTOSIS; BINDING AFFINITY; DNA SYNTHESIS INHIBITION; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; MESENCHYMOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW;

EID: 0032126714     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00047-2     Document Type: Review

References (64)

1. Andress DL, Birnbaum RS Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem. 267:1992;22467-22472.
2. Angelloz-Nicoud P, Harel L, Binoux M Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases. Growth Regul. 6:1996;130-136.
3. Arai T, Clarke J, Parker Aet al. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J Biol Chem. 271:1996;6099-6106.
4. Bang P, Fielder PJ Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology. 138:1997;3912-3917.
5. Baxter RC, Holman SR, Corbould Aet al. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab. 80:1995;2700-2708.
6. Blat C, Villaudy J, Binoux M In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest. 93:1994;2286-2290.
7. Booth BA, Boes M, Bar RS IGFBP-3 proteolysis by plasmin, thrombin, serum, heparin binding, IGF binding, and structure of fragments. Am J Physiol. 271:1996;E465-E470.
8. Booth BA, Boes M, Dake BLet al. Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3. Growth Regul. 6:1996;206-213.
9. Clemmons DR Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 8:1997;45-62.
10. Cohen P, Lamson G, Okajima T, Rosenfeld RG Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol. 7:1993;380-386.
11. Conover CA Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3, studies of underlying mechanism. Endocrinology. 130:1992;3191-3199.
12. Conover CA, Powell DR Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology. 129:1991;710-716.
13. Conover CA, Clarkson JT, Bale LK Factors regulating insulin-like growth factor-binding protein-3 binding, processing, and potentiation of insulin-like growth factor action. Endocrinology. 137:1996;2286-2292.
14. Cox GN, McDermott MJ, Merkel Eet al. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology. 135:1994;1913-1920.
15. Dai Z, Xing Y, Boney CM, Clemmons DR, D'Ercole AJ Human insulin-like growth factor-binding protein-1 (hIGFBP-1) in transgenic mice, characterization and insights into the regulation of IGFBP-1 expression. Endocrinology. 135:1994;1316-1327.
16. Daughaday WH, Kapadia M Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci USA. 86:1989;6778-6782.
17. Davenport ML, Clemmons DR, Miles MVet al. Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology. 127:1990;1278-1286.
18. Davenport ML, Isley WL, Pucilowska JBet al. Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab. 75:1992;590-595.
19. Durham SK, Mohan S, Liu Fet al. Bioactivity of a 29-kilodalton insulin-like growth factor binding protein-3 fragment present in excess in chronic renal failure serum. Pediatr Res. 42:1997;335-341.
20. Fowlkes JL Insulinlike growth factor-binding protein proteolysis, an emerging paradigm in insulinlike growth factor physiology. Trends Endocrinol Metab. 8:1997;299-306.
21. Fowlkes JL, Serra DM, Rosenberg CK, Thrailkill KM Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis. J Biol Chem. 270:1995;27481-27488.
22. Galiano RD, Zhao LL, Clemmons DRet al. Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model. J Clin Invest. 98:1996;2462-2468.
23. Gay E, Seurin D, Babajko Set al. Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice, repercussions on reproduction, ante- and perinatal mortality and postnatal growth. Endocrinology. 138:1997;2937-2947.
24. Gill ZP, Perks CM, Newcomb PV, Holly JM Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 272:1997;25602-25607.
25. Guler HP, Zapf J, Schmid C, Froesch ER Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol. 121:1989;753-758.
26. Hoeck WG, Mukku VR Identification of the major sites of phosphorylation in IGF binding protein-3. J Cell Biochem. 56:1994;262-273.
27. Imai Y, Busby WH Jr., Smith CEet al. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J Clin Invest. 100:1997;2596-2605.
28. Jaques G, Noll K, Wegmann Bet al. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology. 138:1997;1767-1770.
29. Jones JI, Clemmons DR Insulin-like growth factors and their binding proteins, biological actions. Endocr Rev. 16:1995;3-34.
30. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo, effects on affinity for IGF-I. Proc Natl Acad Sci USA. 88:1991;7481-7485.
31. Jones JI, Gockerman A, Busby WH Jr., Camacho-Hubner C, Clemmons DR Extracellular matrix contains insulin-like growth factor binding protein-5, potentiation of the effects of IGF-I. J Cell Biol. 121:1993;679-687.
32. Jones JI, Gockerman A, Busby WH Jr., Wright G, Clemmons DR Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 90:1993;10553-10557.
33. Karas M, Danilenko M, Fishman Det al. Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in Ishikawa endometrial cancer cells. J Biol Chem. 272:1997;16514-16520.
34. Kim HS, Nagalla SR, Oh Yet al. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs), characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA. 94:1997;12981-12986.
35. Lalou C, Silve C, Rosato R, Segovia B, Binoux M Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology. 135:1994;2318-2326.
36. Lalou C, Lassarre C, Binoux M A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology. 137:1996;3206-3212.
37. Lalou C, Sawamura S, Segovia B, Ogawa Y, Binoux M Proteolytic fragments of insulin-like growth factor binding protein-3, N-terminal sequences and relationships between structure and biological activity. C R Acad Sci III. 320:1997;621-628.
38. Lassarre C, Binoux M Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology. 134:1994;1254-1262.
39. Leal SM, Liu Q, Huang SS, Huang JS The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 272:1997;20572-20576.
40. Lee CY, Rechler MM A major portion of the 150-kilodalton insulin-like growth factor-binding protein (IGFBP) complex in adult rat serum contains unoccupied, proteolytically nicked IGFBP-3 that binds IGF-II preferentially. Endocrinology. 136:1995;668-678.
41. Lee CY, Rechler MM Purified rat acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in the absence of IGFs. Endocrinology. 136:1995;4982-4989.
42. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology. 129:1991;2254-2256.
43. Li W, Fawcett J, Widmer HRet al. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology. 138:1997;1763-1766.
44. Martin JL, Baxter RC Transforming growth factor-beta stimulates production of insulin-like growth factor-binding protein-3 by human skin fibroblasts. Endocrinology. 128:1991;1425-1433.
45. McCusker RH, Camacho-Hubner C, Bayne ML, Cascieri MA, Clemmons DR Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells, the modulating effect of cell released IGF binding proteins (IGFBPs). J Cell Physiol. 144:1990;244-253.
46. Mohseni-Zadeh S, Binoux M Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand, an alternative mechanism in the regulation of IGF action. Endocrinology. 138:1997;5645-5648.
47. Nickerson T, Huynh H, Pollak M Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 237:1997;690-693.
48. Oh Y, Muller HL, Pham H, Lamson G, Rosenfeld RG Non-receptor mediated, post-transcriptional regulation of insulin-like growth factor binding protein (IGFBP)-3 in Hs578T human breast cancer cells. Endocrinology. 131:1992;3123-3125.
49. Oh Y, Muller HL, Lamson G, Rosenfeld RG Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 268:1993;14964-14971.
50. Oh Y, Muller HL, Ng L, Rosenfeld RG Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem. 270:1995;13589-13592.
51. Radulescu RT Nuclear localization signal in insulin-like growth factor-binding protein type 3. Trends Biochem Sci. 19:1994;278.
52. Rajah R, Valentinis B, Cohen P Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 272:1997;12181-12188.
53. Rajkumar K, Barron D, Lewitt MS, Murphy LJ Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology. 136:1995;4029-4034.
54. Rechler MM Insulin-like growth factor binding proteins. Vitam Horm. 47:1993;1-114.
55. Rechler MM Growth inhibition by insulin-like growth factor (IGF) binding protein-3 - what's IGF got to do with it [editorial]? Endocrinology. 138:1997;2645-2647.
56. Smith EP, Cheung PT, Ferguson A, Chernausek SD Mechanisms of Sertoli cell insulin-like growth factor (IGF)-binding protein-3 regulation by IGF-I and adenosine 3′5′-monophosphate. Endocrinology. 131:1992;2733-2741.
57. Smith EP, Lu L, Chernausek SD, Klein DJ Insulin-like growth factor-binding protein-3 (IGFBP-3) concentration in rat Sertoli cell-conditioned medium is regulated by a pathway involving association of IGFBP-3 with cell surface proteoglycans. Endocrinology. 135:1994;359-364.
58. Stewart CE, Rotwein P Growth, differentiation, and survival, multiple physiological functions for insulin-like growth factors. Physiol Rev. 76:1996;1005-1026.
59. Timmins AC, Cotterill AM, Hughes SCet al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med. 24:1996;1460-1466.
60. Tsuboi R, Shi CM, Sato C, Cox GN, Ogawa H Co-administration of insulin-like growth factor (IGF)-I and IGF-binding protein-1 stimulates wound healing in animal models. J Invest Dermatol. 104:1995;199-203.
61. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 9:1995;361-367.
62. Yang YW, Yanagishita M, Rechler MM Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells, role of heparan sulfate proteoglycans. Endocrinology. 137:1996;4363-4371.
63. Zadeh SM, Binoux M The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology. 138:1997;3069-3072.
64. Zapf J Insulinlike growth factor binding proteins and tumor hypoglycemia. Trends Endocrinol Metab. 6:1995;37-42.